ABC Arbitrage SA Takes Position in Amedisys, Inc. (NASDAQ:AMED)

ABC Arbitrage SA purchased a new position in Amedisys, Inc. (NASDAQ:AMED) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 27,782 shares of the health services provider’s stock, valued at approximately $2,522,000. ABC Arbitrage SA owned 0.08% of Amedisys as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in AMED. Blue Trust Inc. boosted its holdings in Amedisys by 55.1% in the fourth quarter. Blue Trust Inc. now owns 349 shares of the health services provider’s stock worth $34,000 after acquiring an additional 124 shares in the last quarter. HBW Advisory Services LLC bought a new position in Amedisys in the fourth quarter valued at about $38,000. Versant Capital Management Inc lifted its position in shares of Amedisys by 68.5% during the 4th quarter. Versant Capital Management Inc now owns 450 shares of the health services provider’s stock valued at $41,000 after buying an additional 183 shares in the last quarter. KBC Group NV purchased a new position in shares of Amedisys during the 3rd quarter valued at about $63,000. Finally, Signaturefd LLC raised its stake in Amedisys by 20.9% during the 3rd quarter. Signaturefd LLC now owns 1,367 shares of the health services provider’s stock valued at $132,000 after purchasing an additional 236 shares during the period. 94.36% of the stock is owned by hedge funds and other institutional investors.

Amedisys Stock Down 0.2 %

Shares of AMED opened at $92.60 on Friday. The company has a market capitalization of $3.03 billion, a price-to-earnings ratio of 36.75, a PEG ratio of 1.82 and a beta of 0.73. The stock’s 50-day moving average price is $90.11 and its 200-day moving average price is $93.64. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.05. Amedisys, Inc. has a 52 week low of $82.15 and a 52 week high of $98.95.

Wall Street Analysts Forecast Growth

Separately, Stephens reaffirmed an “equal weight” rating and issued a $101.00 price objective on shares of Amedisys in a research note on Wednesday. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, Amedisys currently has an average rating of “Hold” and a consensus target price of $100.75.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.